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Abstract 
The human neuroblastoma cell line SH-SY5Y is a potentially useful model for the identification 
and characterisation of Nav modulators, but little is known about the pharmacology of their 
endogenously expressed Navs. The aim of this study was to determine the expression of 
endogenous Nav α and β subunits in SH-SY5Y cells using PCR and immunohistochemical 
approaches, and pharmacologically characterise the Nav isoforms endogenously expressed in this 
cell line using electrophysiological and fluorescence approaches. SH-SY5Y human 
neuroblastoma cells were found to endogenously express several Nav isoforms including Nav1.2 
and Nav1.7. Activation of endogenously expressed Navs with veratridine or the scorpion toxin 
OD1 caused membrane depolarization and subsequent Ca2+ influx through voltage-gated L- and 
N-type calcium channels, allowing Nav  activation to be detected with membrane potential and 
fluorescent Ca2 dyes. -Conotoxin TIIIA and ProTxII identified Nav1.2 and Nav1.7 as the major 
contributors of this response. The Nav1.7-selective scorpion toxin OD1 in combination with 
veratridine produced a Nav1.7-selective response, confirming that endogenously expressed 
human Nav1.7 in SH-SY5Y cells is functional and can be synergistically activated, providing a 
new assay format for ligand screening.  
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1. Introduction 
Voltage-gated sodium channels (Nav) are complex transmembrane proteins comprised of a pore-
forming α subunit and accessory β subunits that play an essential role in the initiation and 
propagation of action potentials in excitable cells. To date, apart from the related Nax which 
appears to function as a sodium sensor [1, 2], nine isoforms termed Nav1.1 – Nav1.9 have been 
functionally defined as sodium-selective ion channels [3]. Their distinct tissue distribution and 
amenability to modulation by toxins and drugs has led to significant interest in Nav as therapeutic 
targets in a number of poorly treated conditions ranging from epilepsy to cardiac arrhythmias and 
pain [4]. In recent years Nav1.7 has emerged as an attractive drug target, with expression 
restricted to a subset of nociceptive neurons that is expected to limit on-target side effects of 
pharmacological modulators of Nav1.7 [5]. In addition, loss-of-function mutations in humans 
have highlighted the possibility that Nav1.7 inhibition could produce complete loss of pain 
sensations without dose-limiting side effects [6]. However, it remains unclear if such an effect 
can be translated to the clinic given the lack of subtype-specific Nav1.7 blockers in clinical trials.  
 
Neuroblastoma and other cell lines of neuronal origin have been widely used for the 
identification and characterisation of putative and clinically used therapeutics with activity at 
Nav. In this context, cell lines of human origin, such as SH-SY5Y human neuroblastoma cells, 
are particularly useful as they endogenously express human targets in cell types of neuronal 
origin. However, knowledge of the endogenous Nav  and  subtype expression in these 
neuronal cell lines is incomplete, limiting the interpretation of pharmacological data obtained 
from these cell lines. Using PCR, immunohistochemistry, electrophysiology and fluorescence-
based responses, we have characterised the Nav types expressed in human SH-SY5Y 
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neuroblastoma cells and used toxins to establish assays that can detect modulators of human 
Nav1.2 and/or Nav1.7. 
 
2. Methods 
2.1 Materials 
Veratridine was obtained from Ascent Scientific (Bristol, UK), tetrodotoxin (TTX) was from 
Enzo Life Sciences (Farmingdale, NY, USA) and ProTxII and Agatoxin TK were from Peptides 
International (Lousiville, KY, USA). Synthetic CVID, TIIIA, GIIIA were obtained through total 
synthesis as described previously [7-9]. Scorpion toxin OD1 was prepared by a combination of 
solid-phase peptide synthesis and chemical ligation [10]. All other reagents, unless otherwise 
stated, were obtained from Sigma Aldrich (Castle Hill, NSW, Australia). TTX, veratridine, 
ProTxII, OD1 and TIIIA were routinely diluted in 0.3–0.5 % bovine serum albumin (BSA) 
solution to avoid adsorption to plastic surfaces. 
 
2.2 Cell Culture 
SH-SY5Y human neuroblastoma cells were a kind gift from Victor Diaz (Max Planck Institute 
for Experimental Medicine, Goettingen, Germany). Cells were routinely maintained in RPMI 
medium (Invitrogen, Australia) supplemented with 15 % foetal bovine serum and L-glutamine 
and passaged every 3–5 days using 0.25 % trypsin/EDTA (Invitrogen). Cells were plated at a 
density of 120, 000–150, 000 cells/well on 96-well or 30, 000–50, 000 cells/well on 384-well 
black-walled imaging plates (Corning) 48 h prior to FLIPR assays. For electrophysiological 
studies, SH-SY5Y cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
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containing 4.5 g/L D-glucose, 0.584 g/L L-Glutamine and 110 mg/L sodium pyruvate 
(Invitrogen). DMEM was supplemented with 10 % heat inactivated foetal bovine serum, 1 % 
Penicillin and Streptomycin (10, 000 units/ml and 10, 000 μg/ml, respectively; Invitrogen). Cells 
were passaged every 4–5 days with 0.25 % trypsin (Invitrogen) and plated at low density in 35 x 
10 mm culture dishes (BD Corning, North Ryde, NSW, Australia) at least 24 hours prior to 
electrophysiological recordings. Robust Nav responses were observed over a period of 
approximately 3 years and up to 20 passages. 
 
2.3 Whole-cell patch-clamp electrophysiology 
SH-SY5Y cells were used within 24–72 hours of plating. Only cells with minimal or no 
processes were used. Whole-cell patch-clamp recordings were performed at room temperature 
with fire-polished patch electrodes prepared from borosilicate glass (SDR Clinical Technology, 
Middle Cove, NSW, Australia). Electrode resistance was 3.5–5 MΩ when filled with an internal 
solution containing (composition in mM): 120 CsCl, 5 MgATP, 5 NaCl, 2 CaCl2, 20 HEPES, 10 
EGTA, pH 7.3 and adjusted to 283-286 mOsm. Cells were continuously bathed in a HEPES-
buffered physiological saline (HBS; composition in mM): 155 NaCl, 2.5 KCl, 1.8 CaCl2, 1.2 
MgCl2, 10 HEPES, 10 glucose, pH 7.4 (adjusted with NaOH) and adjusted to 328-331 mOsm. 
Recordings were made with a HEKA EPC-9 amplifier and PULSE software (v 8.8, HEKA 
Elektronik, Lambrecht/Pfalz, Germany). Data was filtered at 4 kHz and sampled at 20 kHz. 
Mean cell capacitance was 4.96 pF and series resistance was 5.9 M, which was compensated 
by 80%. Capacitance transients were compensated and leak subtraction was performed with a 
P/8 protocol except during experiments using veratridine (to avoid subtraction of any 
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veratridine-induced steady state currents). Drugs were applied to cells by superfusion through 
gravity-fed flow pipes (250 µm diameter) positioned directly above the cell.  
 
2.4 Fluorescence measurement of membrane potential changes  
To assess changes in membrane potential, SH-SY5Y cells were loaded with the red membrane 
potential dye (Molecular Devices, Sunnyvale, CA) according to the manufacturer’s instructions. 
In brief, red membrane potential dye (proprietary composition) was reconstituted with a volume 
of physiological salt solution (PSS; composition in mM: NaCl 140, glucose 11.5, KCl 5.9, 
MgCl2 1.4, NaH2PO4 1.2, NaHCO3 5, CaCl2 1.8, HEPES 10) as specified in the manufacturer’s 
instructions and after a wash with PSS, cells were incubated with 100 μl of the membrane 
potential solution at 37 ˚C for 30 min. The cells were then transferred to the FLIPRTETRA+ 
fluorescent plate reader and changes in fluorescence (excitation 510–545 nm; emission 565–625 
nm) in response to addition of agonists was measured every second for 300 s. 
 
2.5 Fluorescence measurement of calcium responses 
SH-SY5Y cells were loaded with the fluorescent calcium dye Fluo-4 by incubating the cells in 
PSS containing 0.3 % bovine serum albumin and 4 μM Fluo-4-AM (Invitrogen) for 30 min at 37 
˚C. To remove extracellular dye and facilitate dye hydrolysis, cells were washed with PSS for 5–
15 min prior to loading of plates into the FLIPRTETRA+ (Molecular Devices, Sunnyvale, CA) 
fluorescent plate reader. Fluorescence (excitation 470–495 nm; emission 515–575 nm) was 
measured using a cooled charge-coupled device (CCD) camera with camera gain and excitation 
intensity adjusted for each plate to yield an average baseline fluorescence value of 1000 AFU. 
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After 10 baseline reads, buffer or antagonists were added and the fluorescence response was 
measured every second for 300 reads, followed by addition of agonists and fluorescence 
measurements every second for a further 300 seconds. For ProTxII, an additional read interval of 
150 reads every 10 s was incorporated prior to addition of agonists to extend the total incubation 
time to 30 min. Raw fluorescence readings were converted to response over baseline using the 
analysis tool of Screenworks 3.1.1.4 (Molecular Devices) and were expressed relative to the 
maximum increase in fluorescence of control responses. 
 
2.6 Immunofluorescence 
SH-SY5Y cells were plated on PDL-coated glass coverslips at a density of 1 x 105 cells/well in 
12 well plates and grown for 48–72 h. After a wash with PBS (phosphate buffered saline; 
Invitrogen) cells were fixed for 30 min at room temperature with Histochoice® MB fixative 
(Solon, OH, USA), permeabilised for 10 min with 0.1 % Triton-X 100 and blocked with 3 % 
BSA for 30 min at room temperature. After a 1 h incubation with rabbit anti-Nav1.7 primary 
antibody (Alomone Labs, Jerusalem), cells were washed several times with PBS and stained with 
anti-rabbit Alexa-488 (Invitrogen) and DAPI to visualize nuclei. Cells were imaged with a Zeiss 
Axiovert 200 Inverted Laser Scanning Confocal microscope using a Plan Apochromat 100 x/1.4 
oil immersion lens. 
 
2.7 Semi-quantitative PCR 
SH-SY5Y cells were grown on 10 cm dishes, washed twice with ice-cold PBS and total RNA 
isolated using the Qiagen RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s 
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instructions with on-column DNA digestion. The Omniscript Reverse Transcription Kit (Qiagen) 
was used to reverse transcribe 1 μg of RNA, as determined by spectrophotometric absorbance at 
260 nm, and 20 ng of the resulting cDNA was amplified using the Platinum® Pfx kit 
(Invitrogen). PCR reactions additionally contained final concentrations of 2 x amplification 
buffer, 0.3 mM dNTP, 1 mM MgCl2, 0.4 μM primers and 1 U Pfx polymerase in a volume of 50 
μl and were amplified under the following conditions: 94 °C for 5 min, 30 cycles of 94 for 15 s, 
60-64 for 30 s, 68 for 1 min and a final extension at 68 for 10 min. Human Nav primers were 
designed using Primer BLAST, and human β subunit primers were as previously described in the 
literature [11] (see Table 1). Plasmids encoding for Nav1.1–1.8 and β1–β3 subunits verified 
amplification of the correct products for each subtype (data not shown). All reaction products 
were analysed on 2% agarose gels and band density was determined using BioRad Quantity One 
V4.5.2 build 70 with background correction. 
 
2.7 Z’ factor determination of assay robustness 
The Z’ factor, a quantitative representation of assay quality, was determined as previously 
described [12], with 48 replicates of a negative control (PSS) and 48 replicates of positive 
controls (50 μM veratridine or 30 nM OD1 + 2 μM veratridine) per plate. Mean and standard 
deviation for positive and negative controls were determined using GraphPad Prism (Version 
4.00, San Diego, California) and the Z’ factor for each plate determined according to the 
following equation: 
Z’ = 1 – ((3SDpositive + 3SDnegative)/(meanpositive – meannegative)) 
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2.8 Data analysis  
Unless otherwise stated, all data are expressed as the mean ± standard error of the mean (SEM) 
determined from at least n = 3 replicates and are representative of at least 2–4 independent 
experiments. To establish concentration-response curves, responses after addition of compounds 
were plotted against agonist concentration and a 4-parameter Hill equation with variable Hill 
slope or a two-site model was fitted to the data using GraphPad Prism (Version 4.00, San Diego, 
California). Potency of agonists and antagonists are reported as the mean  SEM of 3–4 separate 
experiments. Electrophysiological data were analysed with Pulsefit (v 8.8, HEKA Electronics) 
and GraphPad Prism (v 4.0b for Macintosh, GraphPad Software Inc., San Diego, California, 
USA) software. AxographX (Axograph Scientific, Australia) was used to generate all 
electrophysiological images for figures presented. Statistical significance was determined using 
an unpaired student’s t-test with statistical significance defined as p < 0.05 unless otherwise 
stated. 
 
3. Results 
3.1 SH-SY5Y cells endogenously express TTX-sensitive Nav channels 
We assessed expression of human TTX-sensitive and TTX-resistant Nav isoforms and the 
accessory β subunits present in SH-SY5Y cells by semi-quantitative PCR. As previously 
reported, SH-SY5Y cells expressed mainly the TTX-sensitive isoforms Nav1.3 and Nav1.7 as 
well as Nav1.2 (Fig 1 A) [13]. In addition, we also detected some amplification of Nav1.4 and 
Nav1.5. In contrast to previous reports we were unable to detect Nav1.9 [13], while Nav1.7 was 
consistently the most highly expressed Nav isoform in SH-SY5Y cells. In addition, we did not 
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detect Nav1.7 transcripts in the commonly used rat neuronal cell line PC12 or NG108-15 mouse 
neuroblastoma X rat glioma hybrid cells (data not shown). In SH-SY5Y cells, β2 and β3 but not 
β1 or β4 subunits were also amplified (Fig 1 B). We confirmed Nav1.7 protein trafficked 
correctly to the plasma membrane by immunofluorescence (Fig 2 A and B). SH-SY5Y cells 
stained with a Nav1.7 antibody showed fluorescence localized to the plasma membrane (Fig 2 A 
and B), consistent with functional Nav expression. 
 
3.2 Endogenously expressed TTX-sensitive Nav in SH-SY5Y cells are functional and activated by 
veratridine 
To establish that Nav isoforms expressed in SH-SY5Y cells are functional, we assessed voltage-
gated sodium currents in SH-SY5Y cells using whole-cell patch clamp recording. As previously 
reported [14, 15], depolarizing pulses elicited TTX-sensitive INa in undifferentiated SH-SY5Y 
cells (Fig 3 A). The INa, evoked by stepping from –90 mV to 0 mV for 10 ms was blocked by 
TTX in a concentration-dependent manner, with minimal inhibition at 1 nM and marked 
inhibition from 30–300 nM (Fig 3 B and C; pIC50 8.3 ± 0.08 ). Inhibition by TTX was largely 
reversible, as seen by the washout in the time plot in Fig 3 B. 
 
As the sodium channel activator veratridine is commonly used to elicit Nav responses in high-
throughput assays where control over membrane potential is not possible, we also assessed the 
effect of veratridine on INa in SH-SY5Y cells. Veratridine (50 M) was superfused onto SH-
SY5Y cells and a veratridine-induced, sustained tail current evoked by 10 ms depolarization 
steps from –90 mV to 0 mV every 2.5 s (i.e. 5 depolarization steps) at 30 s intervals. Repetitive 
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stimulation of Nav by high frequency depolarization keeps Nav in the open state, permitting 
maximal veratridine binding, and production of a sustained Nav tail current at resting membrane 
potential [16]. This veratridine-induced effect was mediated by TTX-sensitive Nav, as 
superfusion of TTX (1 M) completely abolished veratridine-induced tail currents (Fig 3 D).  
 
Modulation of endogenously expressed Nav isoforms in SH-SY5Y cells by veratridine also 
resulted in membrane potential changes measured using the “red” FLIPR membrane potential 
dye. Addition of veratridine caused concentration-dependent membrane depolarization with an 
EC50 of 28.5 µM (pIC50 4.54 ± 0.06; Fig 3 E) confirming that Nav channels endogenously 
expressed in SH-SY5Y cells are indeed functional and can be activated by veratridine (Fig 3 F). 
The veratridine-induced membrane depolarization was mediated only through activation of TTX-
sensitive Nav, as pre-treatment with TTX (300 nM) completely abolished these responses (Fig 3 
E and F).  
 
In rat cortical synaptosomes and CA1 hippocampal pyramidal neurons, activation of Nav by 
veratridine leads to cell depolarization and downstream influx of Ca2+ [17, 18]. We wanted to 
assess if veratridine-induced Ca2+ influx also occurs in SH-SY5Y cells, and which ion channels 
contribute to this response. Detection of veratridine-induced responses based on fluorescent 
calcium (Ca2+) signalling would also be suitable as a robust and cost-effective Nav assay that 
avoids some of the weaknesses of membrane potential assays which are prone to artefacts and 
costly. Indeed, addition of veratridine caused a concentration-dependent increase in intracellular 
calcium with an EC50 of 12.7 µM (pIC50 4.89 ± 0.11; Fig 4 A). The Hill slope of the veratridine-
induced response was surprisingly steep (3.25  0.9 in the membrane potential assay and 4.2 ± 
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0.6 in the Ca2+ response assay), with small changes in veratridine concentration eliciting large 
increases in fluorescence emission. The Ca2+ responses elicited by veratridine were completely 
abolished in the presence of TTX (300 nM), confirming these responses were mediated solely 
through TTX-sensitive Nav isoforms endogenously expressed in SH-SY5Y cells (Fig 4 A and B). 
The IC50 of TTX-mediated inhibition of veratridine responses was 8.6 nM (pIC50 8.06 ±0.08) 
(Fig 4 B), consistent with the inhibition of TTX-sensitive Nav channels, and best fitted by a 
single site fit. 
 
3.3 L-type and N-type calcium channels contribute to the veratridine-induced response 
To assess which voltage-gated calcium channels contribute to the depolarization-induced Ca2+ 
influx after addition of veratridine, we assessed the effects of nifedipine to block L-type voltage-
gated calcium channels (VGCC) [19], ω-conotoxin CVID to block N-type VGCC [7], and ω-
agatoxin TK to block P/Q-type VGCC [20], on the veratridine-induced responses (Fig 4 C and 
D). Pre-treatment with nifedipine concentration-dependently inhibited veratridine-induced 
responses with an IC50 of 10.7 nM (pIC50 7.97 ± 0.2) (Fig 4 C). However, nifedipine did not 
completely abolish veratridine-induced responses, with 23.9 ± 4.4 % of the response remaining 
in the presence of saturating concentrations of nifedipine. The veratridine-induced response was 
also mediated by N-type VGCC, as CVID also caused a partial (31.8 ± 1.1%) concentration-
dependent block (pIC50 7.7 ± 0.5) of the veratridine-induced response (Fig 4 D). In contrast, the 
Cav2.1 antagonist agatoxin TK did not inhibit veratridine responses (Fig 4 C). Co-addition of 
nifedipine (10 µM) and CVID (1 µM) completely abolished veratridine-mediated responses (Fig 
4 D), confirming only Cav2.2 and nifedipine-sensitive L-type calcium channels were involved.  
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3.4 Nav subtypes contributing to the veratridine-induced response 
We used Nav subtype-specific inhibitors to elucidate the contribution of various Nav subtypes to 
the veratridine-induced Ca2+ response. Although Nav1.2 was not the most abundantly expressed 
Nav isoform in SH-SY5Y cells as determined by RT-PCR, the Nav1.2/1.4-selective blocker 
TIIIA [8] reduced veratridine-induced responses by 42.6 ± 6.8 % (Fig 4 E; n= 4 independent 
experiments) with an IC50 of 290 nM (pIC50 6.54 ± 0.09). This component was mediated 
exclusively by Nav1.2, as the Nav1.4-selective blocker GIIIA [21] failed to inhibit veratridine 
responses (Fig 4 E) at concentrations up to 10 µM. A small but significant (p < 0.05) rightward 
shift of the veratridine concentration-response curve was observed in the presence of TIIIA (1 
µM) (veratridine EC50 45.8 µM; pEC50 4.33 ± 0.16) and TIIIA again decreased the magnitude of 
the response by 41.3 ± 2.8% (Fig 4 F).  
 
The component of the veratridine-induced response observed in the presence of TIIIA was 
completely blocked by the Nav1.7-selective blocker ProTxII [22] (IC50 of 206.9 pM; pIC50 9.68 ± 
0.15, n = 4 independent experiments) consistent with inhibition of Nav1.7 (Fig 4 G). In the 
absence of TIIIA, ProTxII blocked veratridine-induced responses with a two-site fit with IC50s of 
151.7 pM and 56 nM (pIC50 9.82 ± 0.23 and pIC50 7.25 ± 0.26), consistent with high affinity 
inhibition of Nav1.7 and lower affinity inhibition of Nav1.2 and/or Nav1.3 (Fig 4 G). This 
response displayed excellent robustness and reproducibility, with a Z’ factor [12] of 0.7 ± 0.05 
(Fig 4 H) and can be adapted into an assay format that can detect endogenously expressed human 
Nav1.2 or Nav1.7 either together or specifically in the presence of appropriate inhibitors.  
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Inhibition of endogenous Nav currents in SH-SY5Y cells by ProTxII and TIIIA was further 
verified by electrophysiology techniques (Fig 5). Cultured SH-SY5Y cell INa was evoked by 
stepping from –90 mV to 0 mV for 10 ms. As summarized in Fig 5 A-C, ProTxII (30 nM) 
inhibited INa by 41  1.9 % (n = 8; p < 0.0001, one-sample t test), and TIIIA (1 M) inhibited INa 
by 31  2.1 % (n = 6; p < 0.0001, one-sample t test). Co-application revealed an additive effect, 
with 64 % inhibition (n = 2) of INa in the presence of both ProTxII and TIIIA (Figure 5 A-C), 
with the residual TTXs component likely representing current mediated through Nav1.3. In 
contrast, veratridine-evoked Ca2+ responses measured using the FLIPR were completely 
abolished in the presence of both ProTxII and TIIIA (Fig 4 G). 
 
During repetitive Nav activation, veratridine produces a slowly decaying Nav tail current at 
resting membrane potentials [16, 18]. The veratridine-induced, sustained tail current at -90mV 
was partially inhibited by ProTxII (30 nM) and TIIIA (1 M) also (Fig 5 D). In the presence of 
veratridine (50 M), ProTxII (30 nM) inhibited the tail current by 55  7.8 % (n = 13; p < 
0.0001, one-sample t test) and TIIIA (1 M) inhibition was 48  7.7% (n = 6; p = 0.0016, one-
sample t test). When both ProTxII (30 nM) and TIIIA (1 M) were superfused onto cells in the 
presence of veratridine (50 M), 77  13% inhibition was observed (n = 4; p = 0.009, one-
sample t test).  TTX (1 M) completely abolished the tail current (n = 3, data not shown). 
 
These data reveal that Nav1.7 contributes a substantial component to the INa and veratridine-
induced Ca2+ responses in SH-SY5Y cells. To directly isolate the Nav1.7 component from SH-
SY5Y cells we investigated if the scorpion toxin OD1, a Nav1.7-selective sodium channel 
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modulator from the Iranian scorpion Odonthobuthus doriae [10, 23], could activate Nav 
endogenously expressed in SH-SY5Y cells. Exposure to OD1 caused a concentration-dependent 
leftward shift in the veratridine-induced Ca2+ concentration-response curve and markedly 
potentiated sub-threshold veratridine-induced Ca2+ responses (pEC50 8.52 ± 0.02), while 
maximal veratridine-induced responses were not further potentiated  (Fig 6 A and B). At 
veratridine concentrations which did not elicit responses in the absence of OD1 (2 M), the 
OD1-potentiated Ca2+ responses were concentration-dependently inhibited by the Nav1.7 
inhibitor ProTxII (pIC50 8.75 ± 0.13; Fig 6 C), while the Nav1.2/1.4 inhibitor TIIIA had no 
significant effect (data not shown). This response was also amenable to the characterisation of 
small molecule Nav inhibitors used clinically, including trifluoperazine (IC50 3.2 M), 
amitriptyline (IC50 548 nM), lignocaine (IC50 20.9 M), carbamazepine (IC50 64.8 M), 
tetracaine (IC50 447 nM), mexiletine (IC50 12.9 M) and lamorigine (IC50 819 nM) (Fig. 7). 
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4. Discussion 
Cell lines of neuronal origin, including SH-SY5Y human neuroblastoma cells, endogenously 
express Nav with characteristics resembling native Na
+ currents. While these cell lines have been 
used routinely for the identification and characterisation of Nav modulators, little is known about 
the identity and pharmacology of the endogenously expressed Nav subtypes involved. In these 
cells, the alkaloid veratridine activated endogenously expressed Nav1.2 and Nav1.7 identified by 
PCR and immunohistochemistry, producing an influx of Na+ ions and subsequent membrane 
depolarization. This membrane depolarization in turn leads to a Ca2+ influx through 
endogenously expressed voltage-gated L- and N-type calcium channels that can be detected by 
fluorescent Ca2+ dyes such as Fluo-4. The Nav subtypes underlying the veratridine response were 
determined using subtype specific venom peptides, allowing establishment of specific assays for 
Nav1.7 and Nav1.2. 
 
Using PCR, we confirmed that Nav1.2, 1.3 and 1.7 but not Nav1.9 are expressed in SH-SY5Y 
cells [13]. Consistent with a lack of TTX-resistant Nav isoforms, both Ca
2+ and membrane 
potential responses elicited by veratridine were completely abolished by low concentrations of 
TTX. In electrophysiological experiments, we observed inhibition of Nav currents in single SH-
SY5Y cells by TTX with an average IC50 of 4.9 nM (Fig 3 C), confirming functional expression 
of only TTX-sensitive Nav isoforms. However, there was notable heterogeneity in the IC50 of 
TTX observed in individual cells, reflected in an average Hill slope of – 0.6. This heterogeneity 
of TTX potency in the voltage clamp studies likely reflects a spread of expression levels of 
different TTX-sensitive Nav subtypes in SH-SY5Y cells, as Nav1.3 and Nav1.2 are inhibited by 
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TTX with IC50s of 4 [24] and 12 nM [25], respectively, while human Nav1.7 is inhibited at 
slightly higher TTX concentrations with an IC50 of 24 nM [26, 27]. 
 
Although we detected low levels of Nav1.4 mRNA transcript, veratridine has been reported to 
block rather than activate the skeletal muscle Nav isoforms Nav1.4 [28]. Confirming the lack of 
involvement of this muscle subtype in veratridine-induced responses, the Nav1.4 inhibitor GIIIA 
failed to inhibit any significant component of the veratridine-elicited Ca2+ responses. However, 
we were able to confirm for the first time the expression of Nav1.7 in SH-SY5Y cells at the 
protein level, with Nav1.7 immunofluorescence localized predominantly at the plasma 
membrane. This endogenous expression of human Nav1.7 together with functionally relevant β2 
and β3 subunits makes SH-SY5Y cells well suited to the study of native human Nav1.7 
pharmacology. Consistent with the patterns of expression, low concentrations of ProTxII 
inhibited ~ 50% of the response detected by FLIPR Ca2+ measurements and patch clamping, with 
inhibition by TIIIA confirming that most of the remaining component arose from activation of 
Nav1.2 by veratridine.  
 
Pharmacological characterisation of the veratridine-induced responses in SH-SY5Y cells shows 
that despite the relatively high expression of Nav1.3, this isoform does not appear to contribute 
significantly to the veratridine-induced Ca2+ responses. While veratridine has been reported to 
affect gating of most Nav isoforms, albeit with reduced efficacy at Nav1.8 [29], by binding to site 
2 in the S6 segment of the voltage sensor, the relative sensitivity and efficacy of veratridine 
across Nav isoforms has not been established [30]. In addition, veratridine has been reported to 
be a partial agonist in foetal mouse brain cells and rat heart cells [31, 32]. Thus, differences in 
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the sensitivity or efficacy of activation of Nav subtypes by veratridine might contribute to 
preferential activation of endogenously expressed Nav1.2 and Nav1.7 in SH-SY5Y cells. It is also 
unclear if expression of accessory subunits alters activation of Nav isoforms by veratridine. 
Specifically, the altered inactivation kinetics of Nav1.3 in the presence of β3 subunits [33] might 
contribute to the absence of Nav1.3-mediated responses to veratridine. While compounds 
affecting function of VGCC can produce false positives in this system, such artefacts can also 
provide valuable information on putative off-target effects of the test compounds. For example, 
compounds that cause an increase in intracellular Ca2+ upon addition are likely to possess 
undesirable off-target effects and can be excluded immediately from further study. The effect of 
such compounds on VGCC can be easily verified using a K+ depolarization assay and fluorescent 
Ca2+ imaging in SH-SY5Y cells.  
 
Some studies have reported an inability to detect modulation of heterologously expressed Nav1.7 
by gating modifiers such as ProTxI using membrane potential dyes [34]. However, we were able 
to detect inhibition by pore blockers such as tetrodotoxin, µ-conotoxin TIIIA and clinically used 
compounds including amitriptyline and tetracaine (Fig 7), as well as inhibition by the state 
dependent blocker ProTxII through the measurement of Ca2+ fluxes. This discrepancy may 
reflect expression of endogenous sodium channels in SH-SY5Y cells at a more physiological 
membrane potential compared to commonly used over-expression systems such as HEK293 cells 
[35, 36]. In addition, the human Nav in SH-SY5Y cells are co-expressed with functionally 
relevant β-subunits, which could affect inhibition of Nav activity by state-dependent blockers 
such as ProTxII. Thus, this assay is amenable to the measurement of a diverse range of 
modulators of Nav function via detection of changes in Ca
2+ signalling. Using the industry-
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standard FLIPR platform in 96- or 384-well format we achieved a high signal-to-noise ratio (Z’ 
score of 0.7), making this assay suitable for rapid identification of novel Nav blockers. 
  
As an alternative approach to generating Nav1.7 specific responses, we investigated the potential 
of the scorpion toxin OD1, which affects inactivation of Nav1.7 with high specificity [23], to 
synergise with veratridine. Treatment with OD1 caused a marked shift in the veratridine 
concentration-response curve producing responses that are now fully blocked by ProTxII. This 
demonstrates that the delay in Nav1.7 inactivation induced by OD1, in combination with a shift 
in the voltage-dependence of Nav activation elicited by veratridine, generates Ca
2+ influx that is 
mediated solely through Nav1.7. These results confirm the preferential activation of endogenous 
Nav1.7 over Nav1.2 by OD1 [10, 23] and permit assessment of human Nav1.7 responses in an 
endogenous context without the need for addition of antagonists. At high concentrations, OD1 
also effects a hyperpolarizing shift in the voltage of activation of Nav1.7 [23], which presumably 
forms the basis for the small Ca2+ transients elicited by OD1 at high (> 30 nM) but not lower 
concentrations (data not shown). In contrast, at low concentrations OD1 affects the gating of 
Nav1.7 and specifically impairs fast inactivation [10, 23], so that small shifts in the voltage-
dependence of activation induced by veratridine result in synergistic activation of Nav1.7. This 
allosteric interaction of veratridine with OD1 is consistent with their activity at site 3 and 2, 
respectively. 
 
In conclusion, we have characterised Nav endogenously expressed in the human neuroblastoma 
cell line SH-SY5Y and described assays which are able to detect activity of endogenously 
expressed human Nav1.2 and/or Nav1.7. Using this approach, both pore blockers and gating 
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modifiers of human sodium channels could be detected using fluorescence, providing a flexible, 
low cost alternative for the primary identification of novel Nav modulators. 
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Figures and Legends 
Table 1. Primer pairs used for PCR of Nav subtypes and β subunits. Human Nav primers 
were designed using Primer BLAST, and human β subunit primers were as previously described 
in the literature [11]. For each Nav subtype and β subunit, GenBank accession numbers, forward 
and reverse primer sequences, expected PCR product size and locations are listed. 
 
Fig 1. SH-SY5Y cells endogenously express Nav and accessory β subunits. 
Expression of Nav α and accessory β subunits was assessed by semi-quantitative PCR. (A)  
Amplification of endogenously expressed human Nav1.2, Nav1.3, Nav1.4, Nav1.5 and Nav1.7 was 
detected in SH-SY5Y cells, with Nav1.7 being the most abundantly expressed Nav isoforms. (B) 
SH-SY5Y cells endogenously expressed human β2 and β3, but not β1 or β4 subunits. (C) 
Representative gel of Nav 1.1–Nav1.9 subunits endogenously expressed in SH-SY5Y cells. Far 
left and right lanes; size marker (bp) (D) Representative gel of β1–β4 subunits endogenously 
expressed in SH-SY5Y cells. Far left lane; size marker (bp). Data are presented as mean ± SEM 
of n = 3 independent experiments. 
 
Fig 2. Endogenously expressed Nav channels in SH-SY5Y cells are located at the plasma 
membrane. 
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(A) and (B) SH-SY5Y cells stained with an anti-Nav1.7 antibody show fluorescence located 
predominantly at the plasma membrane, indicative of functional Nav expression. Scale bar; 10 
μm. 
 
Fig 3. Endogenously expressed Nav channels in SH-SY5Y cells are functional and TTX-
sensitive. 
[A-D] Whole-cell patch clamp recordings from SH-SY5Y cells. Na+ currents were evoked by 
stepping from -90 mV to 0 mV for 10 ms. (A) Concentration-effect of TTX in a single cell. (B) 
Time plot of peak amplitudes of INa in the presence of increasing concentrations of TTX in a 
single cell (concentrations indicated by bars). (C) Concentration-effect curve of TTX inhibition 
in SH-SY5Y cells (n = 20). TTX blocked INa with an IC50 of 4.9 nM (pIC50 8.3 ± 0.08) (D) 
Veratridine-elicited tail currents are TTX-sensitive. Veratridine-induced tail currents were 
evoked by repeating –90 mV to 0 mV step depolarizations five times over a 2.5 second period, at 
30 second intervals in the presence of 50 M veratridine. A prolonged veratridine-induced tail 
current is rapidly inhibited by TTX (1 M, within 1.5 min of TTX superfusion; time response 
plot not shown).  (E) and (F) The Nav activator veratridine caused a concentration-dependent 
change in membrane potential with an EC50 of 28.5 µM (pEC50 4.54 ± 0.06) that is mediated 
through activation of TTX-sensitive Nav as TTX (300 nM) completely blocked responses. (F) 
Addition of veratridine (50 μM) causes a transient change in membrane potential in SH-SY5Y 
cells mediated through endogenously expressed TTX-sensitive Nav. Data are presented as 
mean ± SEM of n = 3–4 wells and are representative of at least 3 independent experiments.  
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Fig 4. Pharmacological characterization of Ca2+ responses elicited by veratridine in SH-
SY5Y cells 
[A-B] Activation of endogenously expressed TTX-sensitive Nav by veratridine elicits Ca
2+ 
responses in SH-SY5Y cells. (A) Veratridine elicited concentration-dependent increases in 
intracellular Ca2+in SH-SY5Y cells with an EC50 of 12.7 µM (pEC50 4.89 ± 0.10, n=11 
independent experiments). The Ca2+ responses elicited by veratridine were completely blocked in 
the presence of TTX (300 nM), providing evidence that the responses were mediated solely 
through TTX-sensitive Nav isoforms endogenously expressed in SH-SY5Y cells. (B) TTX 
concentration-dependently blocked Ca2+ responses elicited by addition of veratridine (50 μM) 
with an IC50 of 8.6 nM; consistent with the inhibition of TTX-sensitive Nav activated by 
veratridine. [C-D] L-type and N-type VGCC contribute to the veratridine-induced Ca2+response 
in SH-SY5Y cells. (C) The L-type VGCC blocker nifedipine concentration-dependently 
inhibited veratridine-induced responses by 68-88 % (76  4.4 %) with an IC50 of 10.7 nM (pIC50 
7.97 ± 0.2). In contrast, the P/Q-type VGCC blocker agatoxin did not significantly inhibit 
veratridine-elicited Ca2+ responses. (D) The N-type VGCC blocker CVID concentration-
dependently inhibited the veratridine-induced Ca2+ responses by 23-33 % (31.8  1.1 %) with an 
IC50 of 19.7 nM (pIC50 7.7 ± 0.5). Block by CVID together with nifedipine was additive, with 
responses to veratridine completely abolished in the presence of nifedipine (10 μM) and CVID (1 
μM) (open square). [E-F] Veratridine-induced Ca2+ responses are partially mediated by 
activation of endogenously expressed Nav1.2. (E) The Nav1.2/Nav1.4-selective blocker TIIIA 
reduced veratridine-induced responses with an IC50 of 290 nM (pIC50 6.54 ± 0.09). This effect 
was mediated by Nav1.2, as the Nav1.4-selective blocker GIIIA did not affect veratridine 
responses at concentrations up to 10 µM. (F) In the presence of TIIIA (1 µM), the magnitude of 
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the veratridine-induced responses was decreased to 58.7  2.8 % of maximum and there was a 
small but significant (p< 0.05) rightward shift of the veratridine concentration-response curve to 
an EC50 of 45.8 µM (pEC50 4.33 ± 0.16). [G-H] Activation of Nav1.7 contributes to the 
veratridine-induced Ca2+ response in SH-SY5Y cells. (G) In the presence of TIIIA (1 µM), the 
Nav1.7-selective blocker ProTxII concentration-dependently inhibited veratridine-induced 
responses with an IC50 of 206.9 pM (pIC50 9.68 ± 0.15), consistent with inhibition of Nav1.7. In 
the absence of TIIIA, ProTxII concentration-dependently inhibited veratridine-induced responses 
with a two-site fit with IC50s of 151.7 pM and 56 nM (pIC50 9.82 ± 0.23 and pIC50 7.25 ± 0.26), 
respectively. (H) Activation of endogenously expressed Nav1.2 and Nav1.7 by veratridine (50 
M) results in an assay with excellent performance, with Z’ scores of 0.7 ± 0.05. Data are 
presented as mean ± SEM of n = 3-4 wells and are representative of at least 3 independent 
experiments. 
 
Fig 5. ProTxII and TIIIA inhibit endogenously expressed TTX-sensitive Nav in SH-SY5Y 
cells. 
Na+ currents were evoked by stepping from –90 mV to 0 mV for 10 ms.  ProTxII (30 nM) or 
TIIIA (1 M) were initially examined independently of each other, before examining their 
combined inhibitory effects of INa. (A) An illustration showing the progressive inhibition of INa 
by superfusion of ProTxII (30 nM), TIIIA (1 M) and TTX (1 M) in a single SH-SY5Y cell. 
(B) Time plot of a single SH-SY5Y cell showing effects of first ProTxII (30 nM), then ProTxII 
(30 nM) and TIIIA (1 M) superfusion. TTX (1 M) was superfused onto the cell at the end of 
the experiment to inhibit any remaining Nav. Bars indicate the duration of antagonist 
superfusion. (C) ProTxII (30 nM) and TIIIA (1 M) both significantly inhibit INa (p < 0.0001). In 
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two cells, combined application of ProTxII and TIIIA produced greater inhibition of INa than 
either alone. Numbers in brackets above column bars indicate the number of cells examined for 
each antagonist. (D) Veratridine-induced tail currents of endogenously expressed TTX-sensitive 
Nav in SH-SY5Y cells can be inhibited by ProTxII and TIIIA. Veratridine-induced tail currents 
were evoked by repeating -90 mV to 0 mV step depolarizations five times over a 2.5 second 
period, at 30 second intervals in the presence of veratridine (50 M). TIIIA (1 M) or ProTxII 
(30 nM) both significantly (p < 0.001) inhibited veratridine-induced tail currents. Combined 
application of ProTxII and TIIIA produced significantly (p < 0.001) greater inhibition of the 
veratridine-induced tail current than either alone. Numbers in brackets above column bars 
represent the number of cells per respective experiment.   
 
Fig 6. The Nav1.7-selective agonist OD1 potentiates veratridine-induced Ca2+ responses. 
Increases in intracellular Ca2+ were measured in Fluo-4-loaded SH-SY5Y cells using the 
FLIPRTETRA+ plate reader. (A) Treatment with increasing concentrations of OD1 (1-30 nM) 
shifted the veratridine concentration-response curve to the left, without affecting maximal Ca2+ 
responses. Dotted line indicates OD1-potentiated Ca2+ responses in the presence of 2 M 
veratridine. (B) OD1 concentration-dependently potentiated Ca2+ responses induced by 
veratridine (2 M ) with an EC50 of 3.0 nM (pEC50 8.52 ± 0.01, n=3 independent experiments). 
(C) The Nav1.7-specific antagonist ProTxII concentration-dependently inhibited Ca
2+ responses 
elicited by OD1 (30 nM) and veratridine (2 M) with an IC50 of 1.3 nM (pIC50 8.88 ± 0.14, n=3 
independent experiments). Data are presented as mean ± SEM of n = 3-8 wells and are 
representative of at least 2 independent experiments. 
31 
 
 
Fig 7. Veratridine-induced Ca2+ responses in SH-SY5Y cells are amenable to 
pharmacological characterisation of small molecule Nav inhibitors. Vertatridine-induced 
Ca2+ responses in SH-SY5Y cells are concentration-dependently inhibited by clinically used 
small molecule Nav inhibitors, with IC50 values in accordance with literature values. 
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